PLX News and Press, Protalix BioTherapeutics Inc.

2026-02-01 21:27:08 ET Thesis As you know, Protalix Bio Therapeutics ( PLX ) has just announced some news that should serve as a very positive regulatory and clinical milestone for their Fabry disease treatment in Europe. You see, the EMA’s Committee for Medicinal Pro...

2026-01-30 12:53:14 ET More on Protalix BioTherapeutics Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript Protalix, Secarna in agreement to develop rare kidney disorder therapies Protalix BioTherapeutics GAAP EPS of $0.03 misses by $0.03, revenue ...

Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026 If approved by the EC, this dosin...

Protalix BioTherapeutics Letter to Stockholders PR Newswire CARMIEL, Israel , Jan. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative th...

2025-12-22 15:15:19 ET BioMarin Pharmaceutical ( BMRN ) is my favorite in the rare disease therapeutics market thanks to Voxzogo, Palynziq, and Brineura.... Read the full article on Seeking Alpha For further details see: BioMarin: Amicus Buyout Sparks My Enthusiasm

2025-12-17 10:27:20 ET More on Protalix BioTherapeutics Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript Protalix BioTherapeutics GAAP EPS of $0.03 misses by $0.03, revenue of $17.67M misses by $0.2M Protalix BioTherapeutics Q3 Earnings Preview ...

Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement PR Newswire Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator ® platform to jointly develop pharmaceutical candi...

2025-11-13 10:11:45 ET Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript

2025-11-13 06:53:09 ET More on Protalix BioTherapeutics Protalix: Speculative Buy On Promising Plant-Cell Platform And Elfabrio Ramp Protalix BioTherapeutics Q3 Earnings Preview Seeking Alpha’s Quant Rating on Protalix BioTherapeutics Historical earnin...

Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results PR Newswire Company to host conference call and webcast today at 8:00 a.m. EST CARMIEL, Israel , Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a ...